|  Help  |  About  |  Contact Us

Publication : Augmenting the antinociceptive effects of nicotinic acetylcholine receptor activity through lynx1 modulation.

First Author  Nissen NI Year  2018
Journal  PLoS One Volume  13
Issue  7 Pages  e0199643
PubMed ID  29969495 Mgi Jnum  J:263844
Mgi Id  MGI:6189279 Doi  10.1371/journal.pone.0199643
Citation  Nissen NI, et al. (2018) Augmenting the antinociceptive effects of nicotinic acetylcholine receptor activity through lynx1 modulation. PLoS One 13(7):e0199643
abstractText  Neuronal nicotinic acetylcholine receptors (nAChRs) of the cholinergic system have been linked to antinociception, and therefore could be an alternative target for pain alleviation. nAChR activity has been shown to be regulated by the nicotinic modulator, lynx1, which forms stable complexes with nAChRs and has a negative allosteric action on their function. The objective in this study was to investigate the contribution of lynx1 to nicotine-mediated antinociception. Lynx1 contribution was investigated by mRNA expression analysis and electrophysiological responses to nicotine in the dorsal raphe nucleus (DRN), a part of the pain signaling pathway. In vivo antinociception was investigated in a test of nociception, the hot-plate analgesia assay with behavioral pharmacology. Lynx1/alpha4beta2 nAChR interactions were investigated using molecular dynamics computational modeling. Nicotine evoked responses in serotonergic and GABAergic neurons in the DRN are augmented in slices lacking lynx1 (lynx1KO). The antinociceptive effect of nicotine and epibatidine is enhanced in lynx1KO mice and blocked by mecamylamine and DHbetaE. Computer simulations predict preferential binding affinity of lynx1 to the alpha:alpha interface that exists in the stoichiometry of the low sensitivity (alpha4)3(beta2)2 nAChRs. Taken together, these data point to a role of lynx1 in mediating pain signaling in the DRN through preferential affinity to the low sensitivity alpha4beta2 nAChRs. This study suggests that lynx1 is a possible alternative avenue for nociceptive modulation outside of opioid-based strategies.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

6 Bio Entities

Trail: Publication

0 Expression